Naphthalen-2-yloxymethyl-triazol-thiazol-cpd37a
BCHE specific: IC50 eleelACHE >600 microM eqBCHE 0.035 +/- 0.01 microM
General
Type : Naphthalen, Triazol, Thiazol, Sulfur Compound
Chemical_Nomenclature : 2-[(4-Methyl-5-((naphthalen-2-yloxy)methyl)-4H-1,2,4-triazol-3-yl)thio]-N-(thiazol-2-yl)acetamide
Canonical SMILES : O(CC1=NN=C([N]1C)SCC(NC2=NC=CS2)=O)C3=CC4=C(C=C3)C=CC=C4
InChI : InChI=1S\/C19H17N5O2S2\/c1-24-16(11-26-15-7-6-13-4-2-3-5-14(13)10-15)22-23-19(24)28-12-17(25)21-18-20-8-9-27-18\/h2-10H,11-12H2,1H3,(H,20,21,25)
InChIKey : KPLHCLCGOVUCMU-UHFFFAOYSA-N
Other name(s) : Compound 37a || 2-[[5-(naphthalen-2-yloxymethyl)-4-methyl-1,2,4-triazol-3-yl]sulfanyl]-N-(1,3-thiazol-2-yl)propanamide
Target
Families : Naphthalen-2-yloxymethyl-triazol-thiazol-cpd37a ligand of proteins in family
BCHE
Protein :
human-BCHE
References (1)
| Title : Novel 1,2,4-triazole derivatives containing the naphthalene moiety as selective butyrylcholinesterase inhibitors: Design, synthesis, and biological evaluation - Kocak Aslan_2024_Arch.Pharm.(Weinheim)__e2400406 |
| Author(s) : Kocak Aslan E , Sezer A , Tuylu Kucukkilinc T , Palaska E |
| Ref : Arch Pharm (Weinheim) , :e2400406 , 2024 |
| Abstract : |
| PubMedSearch : Kocak Aslan_2024_Arch.Pharm.(Weinheim)__e2400406 |
| PubMedID: 39034293 |